Cargando…

Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

LY231514 (N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethy l]-benzoyl]-L-glutamic acid) is a new folate-based antimetabolite currently in broad phase II clinical evaluation. Previous in vitro studies (C. Shih et al, CancerRes 57: 1116-1123, 1997) have suggested that LY231514 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, V. J., Bewley, J. R., Andis, S. L., Schultz, R. M., Iversen, P. W., Shih, C., Mendelsohn, L. G., Seitz, D. E., Tonkinson, J. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062799/
https://www.ncbi.nlm.nih.gov/pubmed/9717988
_version_ 1782137223578124288
author Chen, V. J.
Bewley, J. R.
Andis, S. L.
Schultz, R. M.
Iversen, P. W.
Shih, C.
Mendelsohn, L. G.
Seitz, D. E.
Tonkinson, J. L.
author_facet Chen, V. J.
Bewley, J. R.
Andis, S. L.
Schultz, R. M.
Iversen, P. W.
Shih, C.
Mendelsohn, L. G.
Seitz, D. E.
Tonkinson, J. L.
author_sort Chen, V. J.
collection PubMed
description LY231514 (N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethy l]-benzoyl]-L-glutamic acid) is a new folate-based antimetabolite currently in broad phase II clinical evaluation. Previous in vitro studies (C. Shih et al, CancerRes 57: 1116-1123, 1997) have suggested that LY231514 could be a multitargeted antifolate (MTA) capable of inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). The present study compared LY231514 with methotrexate, raltitrexed and a glycinamide ribonucleotide formyltransferase inhibitor, LY309887, at 300, 100, 30 and 100 nM, respectively, for their effects on intracellular folate and at 100, 66, 20 and 30 nM respectively, for their effects on nucleoside triphosphate pools in CCRF-CEM cells. Methotrexate induced an accumulation of dihydrofolate species, together with a rapid depletion of ATP, GTP and all of the deoxynucleoside triphosphates. LY309887 caused an accumulation of 10-formyltetrahydrofolate, a rapid loss of ATP, GTP and dATP, but a slower loss in dCTP, dTTP and dGTP. Both LY231514 and raltitrexed had minimal effects on folate pools. In contrast, they caused rapid depletion of dTTP, dCTP and dGTP, but induced an accumulation of dATP at different rates, with raltitrexed doing so about 2.5 times faster. Most of the observed metabolic changes could be understood on the basis of current knowledge of folate and nucleotide metabolism. We concluded that LY231514 was distinct from methotrexate, LY309887 and raltitrexed based on their metabolic effects in CCRF-CEM cells, and that in this cell line the inhibitory effects of LY231514 were exerted primarily against the thymidylate cycle and secondarily against de novo purine biosynthesis.
format Text
id pubmed-2062799
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20627992009-09-10 Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Chen, V. J. Bewley, J. R. Andis, S. L. Schultz, R. M. Iversen, P. W. Shih, C. Mendelsohn, L. G. Seitz, D. E. Tonkinson, J. L. Br J Cancer Research Article LY231514 (N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethy l]-benzoyl]-L-glutamic acid) is a new folate-based antimetabolite currently in broad phase II clinical evaluation. Previous in vitro studies (C. Shih et al, CancerRes 57: 1116-1123, 1997) have suggested that LY231514 could be a multitargeted antifolate (MTA) capable of inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT). The present study compared LY231514 with methotrexate, raltitrexed and a glycinamide ribonucleotide formyltransferase inhibitor, LY309887, at 300, 100, 30 and 100 nM, respectively, for their effects on intracellular folate and at 100, 66, 20 and 30 nM respectively, for their effects on nucleoside triphosphate pools in CCRF-CEM cells. Methotrexate induced an accumulation of dihydrofolate species, together with a rapid depletion of ATP, GTP and all of the deoxynucleoside triphosphates. LY309887 caused an accumulation of 10-formyltetrahydrofolate, a rapid loss of ATP, GTP and dATP, but a slower loss in dCTP, dTTP and dGTP. Both LY231514 and raltitrexed had minimal effects on folate pools. In contrast, they caused rapid depletion of dTTP, dCTP and dGTP, but induced an accumulation of dATP at different rates, with raltitrexed doing so about 2.5 times faster. Most of the observed metabolic changes could be understood on the basis of current knowledge of folate and nucleotide metabolism. We concluded that LY231514 was distinct from methotrexate, LY309887 and raltitrexed based on their metabolic effects in CCRF-CEM cells, and that in this cell line the inhibitory effects of LY231514 were exerted primarily against the thymidylate cycle and secondarily against de novo purine biosynthesis. Nature Publishing Group|1 1998 /pmc/articles/PMC2062799/ /pubmed/9717988 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Chen, V. J.
Bewley, J. R.
Andis, S. L.
Schultz, R. M.
Iversen, P. W.
Shih, C.
Mendelsohn, L. G.
Seitz, D. E.
Tonkinson, J. L.
Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
title Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
title_full Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
title_fullStr Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
title_full_unstemmed Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
title_short Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
title_sort preclinical cellular pharmacology of ly231514 (mta): a comparison with methotrexate, ly309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in ccrf-cem cells.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062799/
https://www.ncbi.nlm.nih.gov/pubmed/9717988
work_keys_str_mv AT chenvj preclinicalcellularpharmacologyofly231514mtaacomparisonwithmethotrexately309887andraltitrexedfortheireffectsonintracellularfolateandnucleosidetriphosphatepoolsinccrfcemcells
AT bewleyjr preclinicalcellularpharmacologyofly231514mtaacomparisonwithmethotrexately309887andraltitrexedfortheireffectsonintracellularfolateandnucleosidetriphosphatepoolsinccrfcemcells
AT andissl preclinicalcellularpharmacologyofly231514mtaacomparisonwithmethotrexately309887andraltitrexedfortheireffectsonintracellularfolateandnucleosidetriphosphatepoolsinccrfcemcells
AT schultzrm preclinicalcellularpharmacologyofly231514mtaacomparisonwithmethotrexately309887andraltitrexedfortheireffectsonintracellularfolateandnucleosidetriphosphatepoolsinccrfcemcells
AT iversenpw preclinicalcellularpharmacologyofly231514mtaacomparisonwithmethotrexately309887andraltitrexedfortheireffectsonintracellularfolateandnucleosidetriphosphatepoolsinccrfcemcells
AT shihc preclinicalcellularpharmacologyofly231514mtaacomparisonwithmethotrexately309887andraltitrexedfortheireffectsonintracellularfolateandnucleosidetriphosphatepoolsinccrfcemcells
AT mendelsohnlg preclinicalcellularpharmacologyofly231514mtaacomparisonwithmethotrexately309887andraltitrexedfortheireffectsonintracellularfolateandnucleosidetriphosphatepoolsinccrfcemcells
AT seitzde preclinicalcellularpharmacologyofly231514mtaacomparisonwithmethotrexately309887andraltitrexedfortheireffectsonintracellularfolateandnucleosidetriphosphatepoolsinccrfcemcells
AT tonkinsonjl preclinicalcellularpharmacologyofly231514mtaacomparisonwithmethotrexately309887andraltitrexedfortheireffectsonintracellularfolateandnucleosidetriphosphatepoolsinccrfcemcells